Document Detail


Encouraging experience with intracardiac transplantation of unselected autologous bone marrow cells concomitant with coronary artery bypass surgery after myocardial infarction.
MedLine Citation:
PMID:  21881326     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Background: Chronic heart failure after myocardial infarction is still a serious problem without a fundamental therapy. Experimental transplantation of bone marrow cells (BMC) into infarcted myocardium resulted in regeneration and functional improvement.Objective: Clinical investigation of safety and efficacy of intracardiac transplantation of unselected autologous BMC. Method: 22 patients scheduled for elective and isolated coronary artery bypass grafting (CABG) with a reduced LVEF due to myocardial infarction were included. Intraoperatively, sternal bone marrow blood was aspirated, and a sterile buffy coat was prepared and applicated. 19 age, LVEF and coronary disease matched patients served as controls. Heart function, geometry, and scar proportion were assessed by echocardiography and Gadolinium-MRI at the time of the operation and 6 months thereafter.Results: Transplanted patients received a mean number of 360 × 10(6) BMC. We did not notice any significant differences in early or late complications in the transplant group as compared to controls. At six months follow up only the transplanted patients showed a significant improvement of NYHA classes from 2.7 to 1.5 and of LVEF from 36 to 43 %, (p < 0.05). Furthermore, only CABG concomitant with BMC-TX led to a significant reduction of left ventricular end diastolic diameter (LVEDD) from 59 to 54 mm and of scar proportion of the infarcted segments from 2.53 to 2.42, (p < 0.05).Conclusion: Intracardiac transplantation of unselected, autologous BMC is safe and feasible. In adjunct with coronary revascularization it leads to an improvement of ventricular geometry and function. Moreover, it reduces myocardial scar proportion and heart failure symptoms.
Authors:
Sebastian Holinski; Birte Schmeck; Benjamin Claus; Hartmut Radtke; Thomas Elgeti; Martin Holzhausen; Wolfgang Konertz
Related Documents :
21109186 - Lipotoxicity and the development of heart failure: moving from mouse to man.
10980216 - Underutilization and clinical benefits of angiotensin-converting enzyme inhibitors in p...
8869136 - Potential role of angiotensin converting enzyme inhibitors in treatment of atherosclero...
22457676 - Reduction in atherosclerotic events: a retrospective study in an outpatient cardiology ...
12439356 - The treatment targets in acute decompensated heart failure.
12537196 - Variation in mortality risk factors with time after coronary artery bypass graft operat...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia     Volume:  17     ISSN:  1341-1098     ISO Abbreviation:  Ann Thorac Cardiovasc Surg     Publication Date:  2011  
Date Detail:
Created Date:  2011-09-01     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9703158     Medline TA:  Ann Thorac Cardiovasc Surg     Country:  Japan    
Other Details:
Languages:  eng     Pagination:  383-9     Citation Subset:  IM    
Affiliation:
Department of Cardiovascular Surgery, Charite, Humboldt University, Berlin, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Do preoperative statins reduce atrial fibrillation after coronary artery bypass grafting?
Next Document:  Adalimumab-associated Pulmonary Cryptococcosis.